Literature DB >> 19858127

Unexpected myopathy associated with a mutation in MYBPC3 and misplacement of the cardiac myosin binding protein C.

Homa Tajsharghi, Trond P Leren, Saba Abdul-Hussein, Mar Tulinius, Leif Brunvand, Hilde M Dahl, Anders Oldfors.   

Abstract

BACKGROUND: Myosin binding protein C (MyBPC) is essential for the structure of the sarcomeres in striated muscle. There is one cardiac specific isoform and two skeletal muscle specific isoforms. Mutations in MYBPC3 encoding the cardiac isoform cause cardiomyopathy. METHODS AND
RESULTS: We have identified an infant with fatal cardiomyopathy due to a homozygous mutation, p.R943X, in MYBPC3. The patient also had an unexpected skeletal myopathy. The patient expressed the cardiac specific MyBPC isoform in skeletal muscle at transcript and protein levels. Numerous muscle fibres expressing the mutant cardiac isoform showed structural abnormalities with disorganisation of sarcomeres and depletion of myosin thick filaments.
CONCLUSIONS: The surprising identification of a skeletal myopathy in this patient was due to aberrant expression of mutant cardiac MyBPC in skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858127     DOI: 10.1136/jmg.2009.072710

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  9 in total

1.  An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia.

Authors:  Cristina Dias; Murat Sincan; Praveen F Cherukuri; Rosemarie Rupps; Yan Huang; Hannah Briemberg; Kathryn Selby; James C Mullikin; Thomas C Markello; David R Adams; William A Gahl; Cornelius F Boerkoel
Journal:  Hum Mutat       Date:  2012-02-28       Impact factor: 4.878

Review 2.  Myosin binding protein-C: an essential protein in skeletal and cardiac muscle.

Authors:  Pradeep K Luther; Anupama Vydyanath
Journal:  J Muscle Res Cell Motil       Date:  2011-01-13       Impact factor: 2.698

3.  Mutations in genes associated with either myopathy or noncompaction.

Authors:  J Finsterer; C Stollberger
Journal:  Herz       Date:  2018-04-20       Impact factor: 1.443

4.  Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects.

Authors:  Marja W Wessels; Johanna C Herkert; Ingrid M Frohn-Mulder; Michiel Dalinghaus; Arthur van den Wijngaard; Ronald R de Krijger; Michelle Michels; Irenaeus Fm de Coo; Yvonne M Hoedemaekers; Dennis Dooijes
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

Review 5.  Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.

Authors:  Lucie Carrier; Giulia Mearini; Konstantina Stathopoulou; Friederike Cuello
Journal:  Gene       Date:  2015-09-08       Impact factor: 3.688

6.  Whole gene sequencing identifies deep-intronic variants with potential functional impact in patients with hypertrophic cardiomyopathy.

Authors:  Rita Mendes de Almeida; Joana Tavares; Sandra Martins; Teresa Carvalho; Francisco J Enguita; Dulce Brito; Maria Carmo-Fonseca; Luís Rocha Lopes
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

Review 7.  A One Health Approach to Hypertrophic Cardiomyopathy.

Authors:  Yu Ueda; Joshua A Stern
Journal:  Yale J Biol Med       Date:  2017-09-25

8.  Myocardial ultrastructure can augment genetic testing for sporadic dilated cardiomyopathy with initial heart failure.

Authors:  Tsunenori Saito; Naoko Saito Sato; Kosuke Mozawa; Akiko Adachi; Yoshihiro Sasaki; Kotoka Nakamura; Eiichiro Oka; Toshiaki Otsuka; Eitaro Kodani; Kuniya Asai; Kyoichi Mizuno; Wataru Shimizu; Roberta A Gottlieb
Journal:  ESC Heart Fail       Date:  2021-09-06

9.  Cardiac myosin binding protein-C plays no regulatory role in skeletal muscle structure and function.

Authors:  Brian Lin; Suresh Govindan; Kyounghwan Lee; Piming Zhao; Renzhi Han; K Elisabeth Runte; Roger Craig; Bradley M Palmer; Sakthivel Sadayappan
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.